Search Clinical Trials in the European Union

Duration
Visits
Safety phase (I)
Intake methods
Benefits
Drugs
Locations
Clinical Specialty
821-840 of 936 trials

PF-07985631: Tolerance Study in Healthy Adults

We are investigating how different amounts of the study medicine PF-07985631 are tolerated by healthy adults. This study will help us understand its effects on the body.

IgA Nephropathy1-2 yearsSafety phase (I)Nephrology

Ketamine for Depression: Brain Imaging Study

We are investigating how different forms of ketamine affect brain function in individuals with depression. This study aims to improve our understanding of how ketamine may help in treating this condition.

Healthy Participants>2 yearsSafety phase (I)Standard MedicinesPsychiatry

Glioblastoma Multiforme: Itraconazole with Radiotherapy and Temozolomide

We are studying whether adding Itraconazole to standard radiotherapy and temozolomide is safe for patients with newly diagnosed glioblastoma. Our goal is to find the best dose and understand its effects on survival and quality of life.

Glioblastoma≤3 monthsSafety phase (I)6-10 visitsNo PlaceboStandard MedicinesNeurologyOncology

Type 2 Diabetes: RO7795081 Study

We are investigating the safety of RO7795081, a new compound for type 2 diabetes and weight control. The study also looks at how this compound affects the processing of other approved medications in the body.

Obesity and Overweight6-12 monthsSafety phase (I)DiabetologyEndocrinologyInternal Medicine

B-cell Non-Hodgkin Lymphomas: CAR-T Cell Therapy

We are testing a new CAR-T cell treatment for patients with B-cell non-Hodgkin lymphomas. The goal is to see how safe and well-tolerated this therapy is.

Non-Hodgkin LymphomaSafety phase (I)HematologyOncology

UTI Vaccine Study for Adults Aged 18-64

We are testing a new vaccine to see if it can safely prevent urinary tract infections caused by E. coli in adults, especially women. The study will compare its effectiveness to a placebo.

Urinary Tract Infections1-2 yearsSafety phase (I)Efficacy phase (II)6-10 visitsStandard MedicinesCost ReimbursementPartially RemoteInfectious DiseasesUrology

BI 3810477: Tolerance Study in Healthy Adults

We are testing how well healthy adults tolerate multiple doses of a new medication called BI 3810477. This study aims to gather important safety information for future use.

Healthy VolunteersSafety phase (I)DermatologyInternal MedicineOphthalmologyOtolaryngologyPediatricsPsychiatry

Debio 1453P: First-in-Human Safety Study

We are testing a new oral medication in healthy adults to see how safe it is and how the body processes it. This study aims to gather important information for future treatments.

Gonorrhoea6-12 monthsSafety phase (I)Infectious DiseasesInternal Medicine

Type 2 Diabetes: NNC9733-0001 Study

We are researching a new medicine, NNC9733-0001, in healthy individuals and those with type 2 diabetes. The goal is to learn more about its effects and potential benefits.

Healthy ParticipantsType 2 Diabetes>2 yearsSafety phase (I)DiabetologyEndocrinology

Blood Cancer Treatment: CCS1477 Study

We are testing the safety and effects of the experimental drug CCS1477 in patients with advanced blood and bone marrow cancers. This study aims to see how well it works alone and in combination with other treatments.

Acute Myeloid Leukaemia (AML)Myelodysplastic Syndrome (MDS)Multiple Myeloma (MM)Safety phase (I)Efficacy phase (II)Post-Trial Drug AccessNo PlaceboInvestigational MedicinesHematologyOncology

Hepatocellular Carcinoma: ALN-BCAT Treatment

We are evaluating a new treatment called ALN-BCAT for patients with liver cancer. The goal is to see how well it works compared to current options.

Advanced or Metastatic Liver Cancer>2 yearsSafety phase (I)HepatologyOncology

Autoimmune Disease: CAR-Expressing NK Cell Therapy

We are testing a new therapy using engineered immune cells for people with active B-cell driven autoimmune diseases. The study aims to assess safety and effectiveness in conditions like lupus and scleroderma.

Systemic Lupus ErythematosusSystemic SclerosisIdiopathic Inflammatory MyopathySafety phase (I)Efficacy phase (II)16-20 visitsNo PlaceboInvestigational MedicinesInfectious DiseasesRheumatology

Type 1 Diabetes: NNC0194-0499 and Semaglutide Study

We are exploring how a new treatment and its combination with semaglutide can help control blood sugar in people with type 1 diabetes. This study aims to improve management options for those living with this condition.

Type 1 Diabetes3-6 monthsSafety phase (I)DiabetologyEndocrinology

Multiple Sclerosis: OBE-CEL Treatment Study

We are testing a new treatment for people with refractory progressive forms of multiple sclerosis. The study aims to assess its safety and how well it may work.

Progressive Multiple Sclerosis>2 yearsSafety phase (I)Neurology

LSD Levels in the Brain: Neuroimaging Study

We are investigating how LSD is processed in the human brain using advanced imaging techniques. This research may help us understand its effects on mental health.

Healthy Participants1-2 yearsSafety phase (I)NeurologyPsychiatry

Advanced Cancer: TH9619 Treatment Study

We are evaluating the safety and potential anticancer effects of a new drug, TH9619, in patients with advanced cancer. This study aims to understand how different doses may work in treating this condition.

Solid TumorsSafety phase (I)Oncology

Oxytocin Infusion: Effects on Sensory Nerves

We are studying how intravenous oxytocin affects sensory nerve responses and cognitive performance in healthy volunteers. This research may help us understand its role in pain perception and inflammation.

Healthy Participants>2 yearsSafety phase (I)≤5 visitsStandard MedicinesNeurologyPsychiatry

GSK4418959 for Solid Tumors: A New Treatment Approach

We are investigating the safety and early effectiveness of the DNA-repair inhibitor GSK4418959 in adults with specific solid tumors. This study looks at the drug alone and with other cancer treatments to see how well it works.

Colorectal Cancer3-6 monthsSafety phase (I)Efficacy phase (II)No PlaceboInvestigational MedicinesCost ReimbursementPartially RemoteOncology

Study on Banned Substances: ESPAMA_3

We are investigating how exposure to substances prohibited by the World Anti-Doping Agency affects healthy volunteers. This study aims to gather initial insights into their impact.

Healthy VolunteersSafety phase (I)

GHF-201: New Drug Safety Study

We are testing a new medication called GHF-201 in healthy adults to see how safe it is and how the body handles it. This study aims to gather important information before it can be used in patients.

Adult Polyglucosan Body DiseaseSafety phase (I)Internal Medicine